Navigation Links
NIH and non-profits sign research and development agreement
Date:5/25/2011

The National Institutes of Health today announced an agreement with two non-profit organizations to accelerate the development of potential clinical therapies for rare blood cancers.

The cooperative research and development agreement has been established as a shared commitment to move therapies for rare blood cancers into clinical proof-of-concept studies so that promising treatments can eventually be commercialized. The agreement is among the University of Kansas Medical Center, Kansas City, The Leukemia & Lymphoma Society (LLS), the NIH Therapeutics for Rare and Neglected Diseases (TRND) program and the Hematology Branch within the National Heart, Lung and Blood Institute.

"The goal of this collaboration, called The Learning Collaborative (TLC) is to bridge the gap in time and resources that often exists between basic research and human testing of potential new treatments and accelerate and make more efficient the delivery of improved therapies to patients with rare blood cancers," said Christopher P. Austin, M.D., director of the TRND program, currently administered by the National Human Genome Research Institute, a part of NIH. "As a result of our work, as the TLC name implies, we plan to learn more about and improve the drug development process for all diseases."

"This agreement recognizes that academic, philanthropic and patient organizations have a role and a responsibility to be active leaders in the drug discovery process," added Roy A. Jensen, M.D., director, The University of Kansas Cancer Center, Kansas City. "I hope this agreement can serve as a model to other academic and patient communities."

The collaboration's first project is a pilot effort under the TRND program that focuses on further development of an existing small molecule drug used to treat arthritis called auranofin. Auranofin will be evaluated as a treatment for relapsed chronic lymphocytic leukemia (CLL) one of the four major types of leukemia and one that typically affects older people. The goal is to accelerate the development of this drug and complete preclinical through clinical trial studies within two years, at which time an industry partner will be engaged.

Approximately 15,000 people in the United States receive a diagnosis of CLL each year.

CLL is currently treated with various chemotherapies, but patients eventually reach a stage where they become resistant to this treatment and can die as a result. In addition, chemotherapy can be quite toxic, whereas auranofin has received regulatory approval and was demonstrated to be reasonably safe and effective in the treatment of arthritis.

"Chronic lymphocytic leukemia is a complex disease that, while treatable, cannot be cured with chemotherapy," said Adrian Wiestner, M.D., Ph.D., an investigator in the NHLBI's Hematology Branch. "There is an especially urgent need to develop novel therapies for chemotherapy-resistant disease, and through this agreement the Hematology Branch can bolster its clinical and translational research program in this disease as well as other hematologic conditions with unmet clinical needs."

"Development of new therapies for diseases like the blood cancers poses both scientific and economic challenges," said Dr. Louis J. DeGennaro, Ph.D., executive vice president and chief mission officer, LLS. "Partnerships are the key to addressing this significant unmet medical need and LLS is proud to add our expertise to this collaboration."


'/>"/>

Contact: Geoff Spencer
spencerg@mail.nih.gov
301-451-8325
NIH/National Human Genome Research Institute
Source:Eurekalert

Related medicine news :

1. Hope Shoppe Inc. Accepts Submissions for Seasons of Hope and Donates Proceeds to Non-Profits
2. VoiceNation Helps Non-Profits Gather Funding for Those in Need
3. Research study reveals profile for female drunk-drivers
4. Research suggests that lipofilling may be safe during conservation treatment for breast cancer
5. 24th ECNP Congress: The most promising data from research across brain disorders
6. MIT research: What makes an image memorable?
7. UTMB researcher receives $3 million NIH grant to study aging in Mexico
8. Researchers Find Cousin of Hepatitis C Virus in Dogs
9. Researchers discover link between obesity gene and breast cancer
10. Mount Sinai researchers discover possible new target for sarcoma treatment and prevention
11. Research provides insight into quality of stored blood used for transfusions
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/28/2017)... ... ... Usually, the impending arrival of warmer weather means the gleeful banishment of ... chin, this means more anxiety than elation. The cosmetic dermatology experts at Cosmetic Laser ... chin is undesirable,” Dr. Goldman said, “but it seems doubly so when the fat ...
(Date:3/28/2017)... ... March 28, 2017 , ... ... release of two biometric time and attendance tracking products: the new NCheck Cloud ... NCheck Cloud Bio Attendance uses biometric face recognition to enable users to check ...
(Date:3/28/2017)... ... ... Columbus OH. Dr. Justin Harper, Founder of Juvly Aesthetics in Ohio and New ... sit on the 2017 National Advisory Board for Allergan’s Facial Aesthetics National Advisory Board., ... the clinic from a small start-up to number 78 in the country based on ...
(Date:3/28/2017)... ... March 28, 2017 , ... The Lice ... Atlantic City March 13-16, was a busy spot this year. Liz Solovay and ... strategies for preventing outbreaks among camp communities during the upcoming 2017 camping season. ...
(Date:3/28/2017)... ... March 28, 2017 , ... Nurse practitioners ... as their value increases in the healthcare workforce, according to a survey recently ... boards, career fairs, and candidate leads to healthcare employers of physicians and advanced ...
Breaking Medicine News(10 mins):
(Date:3/28/2017)... Israel , March 28, 2017 Emosis ... This new business entity, Emosis Ltd, headquartered in Tel ... of novel assays complementing the mother company existing technology platform and ... and sales development of Emosis kits. ... This strategic move starts building Emosis international footprint. ...
(Date:3/28/2017)... 2017  AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a ... commercialization of innovative therapies for the treatment of ... Agency (EMA) has notified the company that the ... Application (MAA) has passed validation, and that the ... MAA for ARX-04 (known as DSUVIA™ in the ...
(Date:3/28/2017)... Mass. , March 28, 2017 ... company developing innovative therapeutics that address significant unmet ... a patent from the Japan Patent Office (JPO) ... connective tissue growth factor (CTGF) for the treatment ... limited to skin fibrosis and proliferative retinopathy (Japanese ...
Breaking Medicine Technology: